Recently, some studies have reported adherence to OAT in patients with NSCLC but have focused on specific targeted therapies, such as tyrosine kinase inhibitors (TKIs) (Timmers et al. 2015; Hess et al. 2017; Rosentreter et al. 2021; Joret et al. 2022) or anaplastic lymphoma kinase inhibitors (ALKis) (Ganti et al. 2022). The gene discussed is ALK; the disease is non-small cell lung carcinoma.